Preventive Antiretroviral Therapy in Non-Thalassemia Carrier Infants Exposed to Mother-to-Child Transmission of HIV Decreases Cord and After Delivery Red Blood Production Without Altering the Development of Hemoglobin.

Preventive Antiretroviral Therapy in Non-Thalassemia Carrier Infants Exposed to Mother-to-Child Transmission of HIV Decreases Cord and After Delivery Red Blood Production Without Altering the Development of Hemoglobin. Curr HIV Res. 2014 Jul 13; Authors: Pornprasert S, Wongnoi R, Oberdorfer P, Sirivatanapa P Abstract Antiretroviral (ARV) prophylaxis for prevention of mother to child transmission (MTCT) of HIV could affect hemoglobin (Hb) development of infants. A cross-sectional descriptive study was conducted in 24 HIV-infected and 21 HIV-uninfected pregnancies. ARV drugs were administered to HIV-infected pregnancies at 21 weeks of gestational age and at the labor. Their infants received zidovudine (ZDV) until 4 weeks of age. Blood sample of ARV-exposed and -unexposed infants were collected at delivery, 1, 2 and 4 months of age. Molecular analyses for α-thalassemia-1 Southeast Asian (SEA) type deletion, β-thalassemia mutations and Hb E were performed for excluding the thalassemia carrier infants. Hemoglobinopathy and Hb A, Hb F and Hb A2 were analyzed by using capillary electrophoresis (CE) while hematological parameters were measured using an automated blood counter. At delivery, 1 and 2 months of age, ARV-exposed infants had significantly lower levels of RBC counts than ARV-unexposed infants (3.56 vs 4.90, 2.66 vs 4.62 and 3.01 vs 4.05 x1012/L; P <0.001, <0.001 and 0.001, respectively). At delivery, there was a trend for l...
Source: Current HIV Research - Category: Infectious Diseases Authors: Tags: Curr HIV Res Source Type: research